Experience with mepolizumab in adults with severe eosinophilic asthma: a case series from India

Maturu, Venkata Nagarjuna; Meshram, Priti; Das, Soumya; Rajput, Ashok Kumar; Kotaru, Arun Chowdary; Kotak, Bhavesh; Markandeywar, Neeraj; Chhatwal, Simran

Severe asthma can be associated with eosinophilic or allergic phenotypes or both. Eosinophilic inflammation is associated with exacerbations and disease severity due to biological activity of interleukin‐5 (IL‐5). Patients with severe asthma have reported reduced lung function and poor health‐related quality of life (HRQoL) and may require systemic corticosteroids for its management. Thus, treatment targeting IL‐5 can help improve quality of life and reduce the use of systemic corticosteroids in severe asthma. Mepolizumab is approved for treating severe eosinophilic asthma as it helps reduce exacerbations, improve lung function and asthma control, and reduce the use of systemic glucocorticoids. This further helps in enhancing HRQoL of these patients. This case series includes four adult patients suffering from severe eosinophilic asthma who were treated with mepolizumab.